AlphaCore Capital
NBIX icon

AlphaCore Capital’s Neurocrine Biosciences NBIX Stock Holding History

AlphaCore Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$666K Buy
4,698
+478
+11% +$76.8K 0.01% 673
2026
Q2 		$711K Buy
4,220
+1,571
+59% +$233K 0.01% 556
2026
Q1 		$349K Buy
+2,649
New +$351K 0.01% 651

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

AlphaCore Capital's NBIX Position: Q3 2026 in Review

AlphaCore Capital increased its Neurocrine Biosciences (NBIX) stake by 11% in Q3 2026, buying an estimated $76.8K and bringing the position to 4,698 shares worth $666K. The position accounts for 0.01% of the portfolio, ranked #673.

AlphaCore Capital first reported a position in NBIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $711K in Q2 2026. 365 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • AlphaCore Capital held 4,698 shares of Neurocrine Biosciences worth $666K as of Q3 2026.
  • AlphaCore Capital bought 478 Neurocrine Biosciences shares in Q3 2026, an estimated $76.8K.
  • Neurocrine Biosciences made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #673 holding.
  • AlphaCore Capital first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 3 quarters since.
  • AlphaCore Capital's Neurocrine Biosciences position peaked at $711K in Q2 2026.
  • 365 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.